Raymond James Financial Services Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-19,300	Closed	-$55K	–	2533
2017 Q3	$55K	Buy	+19,300	New	+$628K	﹤0.01%	2446
2017 Q2	–	Sell	-28,200	Closed	-$44K	–	2518
2017 Q1	$44K	Sell	28,200 -400	-1%	-$14.1K	﹤0.01%	2324
2016 Q4	$33K	Sell	28,600 -16,400	-36%	-$434K	﹤0.01%	2260
2016 Q3	$38K	Sell	45,000 -6,600	-13%	-$224K	﹤0.01%	2221
2016 Q2	$103K	Buy	51,600 +32,100	+165%	+$1.07M	﹤0.01%	2100
2016 Q1	$4K	Buy	+19,500	New	+$425K	﹤0.01%	2071

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's ACAD Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 14,670 shares — an estimated $276K sold.

Raymond James Financial Services Advisors first reported a position in ACAD in Q3 2015 and held it in 23 quarters. The position peaked at $2.15M in Q2 2016. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

Raymond James Financial Services Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 14,670 Acadia Pharmaceuticals shares in Q2 2023, an estimated $276K.
Raymond James Financial Services Advisors first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 23 quarters.
Raymond James Financial Services Advisors's Acadia Pharmaceuticals position peaked at $2.15M in Q2 2016.
236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.